MedTrace Logo

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

NCT02756624 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 516

Last updated 2017-09-11

Study results available
· View outcomes & findings →

Summary

This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution

Conditions

  • Healthy Subjects

Interventions

DRUG

AC-170 0.24%

DRUG

AC-170 Vehicle

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Nicox Ophthalmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Eugene Protzko, MD · Sedeinberg Protzko Eye Associates

  • Ranjan Malhotra, MD · Ophthalmology Associates

  • Stacey Ackerman, MD · Philadelphia Eye Associates

  • M. Ali Haider, DO · Haider Eye Care

  • Robert Rice, MD · R&R Eye Research

  • Gail Torkildsen, MD · Andover Eye Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02756624 on ClinicalTrials.gov